Skip to content
lifestyle.buyersdesire.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aquestive Therapeutics, Inc.
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
May 12, 2026
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
May 6, 2026
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
March 30, 2026
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
March 20, 2026
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
March 14, 2026
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
March 12, 2026
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
March 11, 2026
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
March 11, 2026
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
March 11, 2026
1
2
Next Page
→